Physician profile
Umar Farooq
NPI 1972796621
$100,236.28
in general payments reported to CMS, 2019-2025
16 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $1,569 · 2021: $20K · 2022: $73K · 2023: $5,159 · 2024: $134 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,330 · Travel and Lodging: $1,293 · Food and Beverage: $779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,330.00 |
| Travel and Lodging | $1,293.25 |
| Food and Beverage | $778.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $87,338.65 | 2021-2023 | |
| Horizon Therapeutics Plc | $11,063.18 | 2020-2022 | |
| Roche Products Limited | $1,134.44 | 2023 | Gazyva |
| Astrazeneca Pharmaceuticals LP | $182.00 | 2019-2024 | Lokelma |
| Allergan, INC. | $114.32 | 2020 | |
| Opko Pharmaceuticals, LLC | $111.30 | 2019 | |
| Amgen INC. | $109.62 | 2025 | Tavneos |
| Lilly USA, LLC | $78.11 | 2019-2021 | |
| Abiomed | $41.38 | 2024 | Impella |
| Aurinia Pharma U.S., INC. | $19.69 | 2022 | |
| Glaxosmithkline, LLC. | $16.27 | 2019 | |
| Abbvie INC. | $14.77 | 2022 | |
| Amarin Pharma, INC. | $12.55 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umar Farooq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.